Italian regulators ordered Meta on Wednesday to open its WhatsApp chat platform to rival AI chatbots as it and EU authorities pursue a probe that the US tech giant is abusing its dominant market position.

According to the European Automobile Manufacturers' Association (ACEA) November report on EU car registrations, the figure for Tesla Inc.

BYD's registrations in the European Union were up 235.2% in November to 16,158, according to the European Automobile Manufacturers' Association (ACEA).

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options.

Intel Corp (NASDAQ:INTC, XETRA:INL) shares fell on Wednesday on a Reuters report that Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) had halted a test of Intel's advanced 18A chipmaking process. According to Reuters, which cited two people familiar with the matter, Nvidia had been evaluating whether its chips could be manufactured using Intel's 18A process, one of Intel's most advanced production technologies.

TTM Technologies (TTMI) is a critical supplier to the AI hardware and defense sectors, with 22% y/y sales growth and record earnings. TTMI's growth is driven by surging AI data center demand and robust aerospace & defense spending, with 80% of Q3 sales tied to these arenas. Despite a 189% YTD stock surge, TTMI trades at a discount on PEG and price/sales metrics relative to sector growth, justifying a Strong Buy rating.

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.

FS KKR Capital is cutting its base cash dividend by 29.7% to $0.45 per share, with the BDC's yield now the largest versus its large-cap peers. The move comes as NAV per share grew marginally during the third quarter by 6 cents sequentially, against what's been a broader decline since 2023. FSK is trading at a material 34% discount to NAV, with the move to reduce its dividend set to be helpful to drive a recovery and a possible discount narrowing.

JPM is weighing crypto trading for institutions as regulation eases, signaling a shift that could add liquidity and intensify competition.

Some may doubt the Santa Rally this year amid AI overvaluation and inflation woes. Low P/E momentum ETFs -- XMVM, XSVM, PYZ, VAMO -- offer a balanced year-end play.

Transaction in Own Shares 24 December, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 24 December, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 24/12/2025 358,799 27.1400 27.0150 27.0785 LSE GBP 24/12/2025 - - - - Chi-X (CXE) GBP 24/12/2025 - - - - BATS (BXE) GBP 24/12/2025 309,528 31.1650 31.0100 …

Consumer bundle planned for Q2 2026 pairsMudra Link with Rokid Glasses, with live demos at CES 2026 Yokneam Illit, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a collaboration with Rokid – a global pioneer in human-computer interaction and augmented reality, to deliver gesture control for AI and augmented reality (“AR”) glasses that feels natural, fast and consistent in daily use.

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this movie before. A company leans hard on a single product, rides momentum while it lasts, then scrambles when conditions change.

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials. Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef.

Meta Platforms, Inc. (NASDAQ: META) shares closed slightly higher during Tuesday's session.

Graham (GHM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PSX, VLO and OII stand out heading into 2026, as refining strength, low crude costs and resilient oilfield service demand offset softer oil prices.

SAN FRANCISCO , Dec. 24, 2025 /PRNewswire/ -- A securities class action lawsuit styled Barry v. Coupang, Inc., et al.

The iShares MSCI Spain ETF surged in 2025, driven by attractive valuations, an improved earnings outlook for financial stocks, and a stronger EUR. Looking ahead to 2026, the return outlook for EWP remains robust as Spanish GDP growth continues to outperform European peers, a boost to the ETF's overweight position in cyclical sectors. EWP offers a well-covered dividend of 2.28%, although growth has been erratic due to a sizable allocation to financial stocks.